Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation. Issue 8 (3rd August 2017)

• Record Type: Journal Article
• Authors: Shah, Gunjan L.; Landau, Heather; Londono, Dory; Devlin, Sean M.; Kosuri, Satyajit; Lesokhin, Alexander M.; Lendvai, Nikoletta; Hassoun, Hani; Chung, David J.; Koehne, Guenther; Jhanwar, Suresh C.; Landgren, Ola; Levine, Ross; Giralt, Sergio A.
• Is Part Of: Leukemia & lymphoma. Volume 58:Issue 8(2017)
• Page Start: 1823
• Page End: 1831
• Publication Date: 2017-08-03
• Subjects: Neoplasia -- myeloma -- marrow and stem cell transplantation -- clinical results -- neoplasia – molecular genetics -- neoplasia – cytogenetics; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2016.1260126
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: We aimed to identify whether the use of autologous hematopoietic cell transplantation (HCT) impacts outcomes for multiple myeloma patients with gains of chromosome 1q (+1q). We retrospectively identified 95 patients, 21% having +1q. For patients with +1q, the overall response rate to induction was 85%, with 40% having ≥ VGPR and 20% achieving a CR, similar to non +1q patients ( p = .64). The median PFS from diagnosis with +1q was 2.1 years (95% CI: 1.2–not reached (NR)) vs 4.3 years (95% CI: 3.3 yrs–NR) without +1q ( p = .003). Median OS from diagnosis was 4.4 years (95% CI: 2.9–NR) vs not reached, respectively ( p = .005). On molecular analysis using the Foundation One Heme assay, the most common mutations seen in +1q patients included TP53 (38%) and KRAS (25%). Overall, gain of 1q portends worse PFS and OS which was not negated by auto HCT. Such patients will likely require additional therapy to improve their survival.